Greg Pyszczymuka compensation by year
AYTU BIOPHARMA Summary Compensation Table · the one fiscal year held| Component | FY2026 |
|---|---|
| Salary | $434,300 |
| Bonus | $0 |
| Stock awards | $23,750 |
| Option awards | $0 |
| Non-equity incentive | $84,357 |
| Pension and deferred compensation | $0 |
| All other | $16,511 |
| Total | $558,918 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: AYTU BIOPHARMA, INC DEF 14A filed October 22, 2026, accession 0001437749-26-033276, and prior-year filings. Open the filing on EDGAR.
How this page was built: the AYTU BIOPHARMA, INC filed document, accession 0001437749-26-033276. Every figure is read from that document and cited to the page and table it appears in. Filed October 22, 2026.
Equity holdings
unvested awards at FY2026 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 12,500 | $26,875 | — |
| Option | 391 | — | $1.73 |
| Option | 3,322 | — | $1.84 |
Per the Outstanding Equity Awards at Fiscal Year-End table in AYTU BIOPHARMA, INC's FY2026 proxy; value at the fiscal year-end close, as the company printed it.
AYTU BIOPHARMA’s named executive officers, FY2026
as the company reported each| Named executive officer | Role | FY2026 total |
|---|---|---|
| Joshua Disbrow | Chief Executive Officer since April 2015 | $844,854 |
| Ryan Selhorn | Chief Financial Officer, Corporate Secretary and Treasurer since November 2024 | $566,212 |
| Greg Pyszczymuka · this page | Chief Commercial Officer since January 2022 | $558,918 |
| Jarrett Disbrow | Chief Business Officer since November 2022 | $534,379 |
The full AYTU BIOPHARMA compensation record
free company briefThis page is one person within AYTU BIOPHARMA's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the AYTU BIOPHARMA proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are AYTU BIOPHARMA's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.